News
UK MHRA grants conditional approval for Exkivity in EGFR Exon20ins+ NSCLC.
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to Exkivity (mobocertinib), from Takeda, as a monotherapy treatment for adult patients with epidermal growth factor receptor (EGFR) locally advanced or metastatic non-small cell lung cancer.
The patients involved will have received prior platinum-based chemotherapy. EGFR Exon20ins+ NSCLC (non-small cell lung cancer) primarily affects younger people and non-smokers and carries a worse prognosis than other EGFR mutations.
Condition: NSCLC / EGFR
Type: drug